Nanobiotix SA (Nanobiotix) designs and manufactures nanomedicines for the treatment of cancer. The company is evaluating its lead product candidate NBTXR3 against soft tissue sarcoma, pancreatic, liver, rectal, prostate, head and neck cancers; Non-small cell lung cancer (NSCLC); recurrent head and neck, lung or liver metastasis. Its product candidate consists of nanoparticles delivered through one time intratumoral injection and are activated by radiation therapy. The company is a spin-off from the University of Buffalo in New York. It has operations in the US, Spain and Germany. Nanobiotix is headquartered in Paris, Ile-de-France, France.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Note: Some sections may be missing if data is unavailable for the company
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Nanobiotix SA
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Nanobiotix SA Company Overview
- Nanobiotix SA Company Snapshot
- Nanobiotix SA Pipeline Products and Ongoing Clinical Trials Overview
- Nanobiotix SA - Pipeline Analysis Overview
- Nanobiotix SA - Key Facts
- Nanobiotix SA - Major Products and Services
- Nanobiotix SA Pipeline Products by Development Stage
- Nanobiotix SA Ongoing Clinical Trials by Trial Status
- Nanobiotix SA Pipeline Products Overview
- Hensify - Breast Cancer
- Hensify - Breast Cancer Product Overview
- Hensify - Esophageal Cancer
- Hensify - Esophageal Cancer Product Overview
- Hensify - Gastrointestinal Cancer
- Hensify - Gastrointestinal Cancer Product Overview
- Hensify - Genitourinary Cancer
- Hensify - Genitourinary Cancer Product Overview
- Hensify - Glioblastoma
- Hensify - Glioblastoma Product Overview
- Hensify - H&N & Lung Cancer
- Hensify - H&N & Lung Cancer Product Overview
- Hensify - Head & Neck Cancer
- Hensify - Head & Neck Cancer Product Overview
- Hensify - Head & Neck Cancer Clinical Trial
- Hensify - Liver Cancer
- Hensify - Liver Cancer Product Overview
- Hensify - Lung Cancer
- Hensify - Lung Cancer Product Overview
- Hensify - Lung Cancer Clinical Trial
- Hensify - Prostate Cancer
- Hensify - Prostate Cancer Product Overview
- Hensify - Rectal Cancer
- Hensify - Rectal Cancer Product Overview
- Hensify - Rectal Cancer Clinical Trial
- Hensify - Soft Tissue Sarcoma
- Hensify - Soft Tissue Sarcoma Product Overview
- NanoMag
- NanoMag Product Overview
- NanoPDT
- NanoPDT Product Overview
- Nanobiotix SA - Key Competitors
- Nanobiotix SA - Key Employees
- Nanobiotix SA - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
Recent Developments
Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Transgene SA
- NH TherAguix SAS
- Nanospectra Biosciences Inc
- MedinCell SA
- MagForce AG
- ERYTECH Pharma SA
- Cellectis SA
